



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of
Serion

Serial No: 09/367,712

Filed: August 18, 1999

For: TAZAROTENE AND CORTICO-
STEROID TREATMENT FOR PSORIASIS

Group Art Unit: 1616

Examiner: B. Badio

DOCKET NO. 17224(AP)
PATENT

RECEIVED
JUN - 9 2000
TC 1600 MAIL ROOM

Amendment

Box Non Fee Amendment

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Dear Sir:

The Office Action of March 1, 2000 has been received and carefully studied. In response, the following amendments are made.

[Please make the following changes in the claims:]

Sub C
1. (Amended) A method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a mid- or high-potency corticosteroid.

2. (Amended) The method of claim 1 wherein said corticosteroid is selected from the group consisting of alclometasone dipropionate, [fluocinolone acetonide,] mometasone furoate, fluocinonide, [diflorasone diacetate, fluticasone propionate, betamethasone dipropionate, clobetasol propionate,] and betamethasone valerate.

Cancel claim 4.

5. (Amended) The method of claim [4] 2 wherein said corticosteroid is selected from the group consisting of mometasone furoate and alclometasone dipropionate ~~fluocinolone acetonide~~.

Sub C
6. (Amended) A method for treating psoriasis in a human subject by topically applying to the psoriatic skin of said subject an effective amount of tazarotene and an effective amount of a mid-or high-potency corticosteroid.